期刊
ANNALS OF CLINICAL PSYCHIATRY
卷 33, 期 4, 页码 E10-E20出版社
QUADRANT HEALTHCOM INC
DOI: 10.12788/ACP.0048
关键词
-
类别
资金
- Massachusetts General Hospital Department of Psychiatry's T32 training grant [T32MH112485]
- Department of Veterans Affairs (VA) Clinical Science Research and Development, Career Development Award (CDA-1) [IK1 CX002187]
- Department of VA Mid-Atlantic Mental Illness Research, Education, and Clinical Center (MIRECC)
Ketamine has evolved from an anesthetic to a rapid treatment for mood disorders and suicidal ideation. Evidence supports its effectiveness in treating depression and suicidality, with potential benefits for anxiety and PTSD, but further research is needed. Intranasal esketamine has been FDA-approved for depression treatment, highlighting recent developments in the field.
BACKGROUND: Mood disorders are a leading cause of morbidity. Many patients experience treatment-resistant depression (TRD), and suicide rates are rising. Faster-acting and more effective antidepressant medications are needed. Four decades of research has transformed the use of ketamine from an anesthetic to an outpatient treatment for major depressive disorder (MDD). Ketamine is a N-methyl-D-aspartate (NMDA) receptor antagonist and has been shown to rapidly improve mood symptoms and suicidal ideation by targeting the glutamate system directly. METHODS: We used the PubMed database to identify relevant articles published until September 1, 2020. We focused on meta-analyses, randomized controlled trials, and original observational studies. We included relevant studies for depression, MDD, TRD, bipolar disorder, anxiety, posttraumatic stress disorder (PTSD), suicide, ketamine, and esketamine. RESULTS: Both racemic ketamine and esketamine have been shown to rapidly treat depression and suicidality. There is evidence that ketamine can be helpful for anxiety and PTSD; however, more research is needed. Intranasal esketamine has been FDA-approved to treat depression. CONCLUSIONS: This narrative review describes the evolution of ketamine to treat mood disorders and suicidality. We provide the evidence supporting recent developments using esketamine as well as unresolved issues in the field, such as dosing and safety.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据